Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
复制标题
Siglec-9，多种癌症类型中癌症进展的推定免疫检查点标记物
DOI：
10.3389/fmolb.2022.743515
复制
发表时间：
2022
影响因子：
5
通讯作者：
Liu S
中科院分区：
文献类型：
--
作者：
Wu Y;Huang W;Xie Y;Wang C;Luo N;Chen Y;Wang L;Cheng Z;Gao Z;Liu S
Siglec-9是一种细胞表面跨膜受体，主要表达于B细胞、CD56+NK细胞以及CD4+和CD8+T细胞，与肿瘤免疫微环境密切相关。然而，Siglec-9的表达模式及其预后潜力尚未从泛癌的角度进行研究。本研究旨在探讨Siglec-9与泛癌预后、肿瘤分期、分子亚型及免疫微环境的关系。Siglec-9的mRNA表达来自癌症基因组图谱(TCGA)、博德研究所肿瘤细胞系百科全书(CCLE)和基因-组织表达(GTEx)。Kaplan-Meier分析评价Siglec-9mRNA表达与预后的关系。在肿瘤免疫评估资源(TIMER)和肿瘤-免疫系统相互作用综合信息库门户(TISIDB)上评估Siglec-9与肿瘤浸润性免疫细胞、免疫亚型和分子亚型的相关性。分析Siglec-9表达与免疫检查点、错配修复(MMR)、DNA甲基转移酶(DNMT)、肿瘤突变负荷(TMB)和微卫星不稳定性(MSI)的关系。结果表明，Siglec-9在大多数TCGA肿瘤中的表达明显改变。Siglec-9的表达与肾上腺皮质癌(ACC)、肺腺癌(LUSC)、胸腺瘤(Thym)、结肠腺癌(Coad)、多形性胶质母细胞瘤(GBM)、前列腺癌(PRAD)、食道癌(ESCA)和脑低级别胶质瘤(LGG)的预后相关。尤其是在LGG中，Siglec-9的高表达与预后不良密切相关。Siglec-9的表达与肿瘤分期也有相关性。此外，Siglec-9与免疫细胞的渗透呈正相关，包括中性粒细胞、树突状细胞(DC)、巨噬细胞以及CD4+和CD8+T细胞。此外，在多种肿瘤中，Siglec-9与MSI、TMB、MMR、DNMT、免疫检查点、免疫亚型、分子亚型和免疫调节剂显著相关。具体地说，中国胶质瘤基因组图谱(CGGA)中的LGG数据集验证了较差的预后价值和与免疫细胞浸润的强相关性。这些发现表明，Siglec-9可以成为一种新的生物标志物和癌症免疫治疗的潜在靶点。
Siglec-9, a cell surface transmembrane receptor mainly expressed on B cells, CD56+ NK cells, and CD4+ and CD8+ T cells, is strongly related to the tumor immune microenvironment. However, the expression pattern of Siglec-9 and its prognostic potential have not been investigated in a pan-cancer perspective. This study aimed to explore the association of Siglec-9 with prognosis, tumor stage, molecular subtype, and the immune microenvironment in pan-cancer. The mRNA expression of Siglec-9 was obtained from The Cancer Genome Atlas (TCGA), the Broad Institute Cancer Cell Line Encyclopedia (CCLE), and Genotype-Tissue Expression (GTEx). The relationship between Siglec-9 mRNA expression and prognosis was evaluated by the Kaplan–Meier analysis. The correlation between Siglec-9 and tumor-infiltrating immune cells, immune subtype, and molecular subtype was evaluated on Tumor Immune Estimation Resource (TIMER) and Integrated Repository Portal for Tumor-Immune System Interactions (TISIDB). The correlation between Siglec-9 expression and immune checkpoint, mismatch repair (MMR), DNA methyltransferase (DNMT), tumor mutation burden (TMB), and microsatellite instability (MSI) was also analyzed. It showed that Siglec-9 expression was significantly altered in most TCGA tumors. Siglec-9 expression was associated with the prognosis of patients with adrenocortical carcinoma (ACC), lung adenocarcinoma (LUSC), thymoma (THYM), colon adenocarcinoma (COAD), glioblastoma multiforme (GBM), prostate adenocarcinoma (PRAD), esophageal carcinoma (ESCA), and brain lower-grade glioma (LGG). Particularly, increased Siglec-9 expression was strongly correlated with poor prognosis in LGG. Correlation between Siglec-9 expression and tumor stage was also observed in various cancers. In addition, Siglec-9 was positively associated with infiltration of immune cells including neutrophils, dendritic cells (DCs), macrophage, and CD4+ and CD8+ T cells. Moreover, a significant correlation between Siglec-9 and MSI, TMB, MMR, DNMT, immune checkpoint, immune subtype, molecular subtype, and immunomodulators was observed in multiple cancers. Specifically, poor prognostic value and strong correlation to immune cell infiltration were verified with the LGG dataset from the Chinese Glioma Genome Atlas (CGGA). These findings indicated that Siglec-9 can be a novel biomarker and a potential target for cancer immunotherapy.
登录
查看更多内容
放射组学特征作为低级别神经胶质瘤患者无进展生存的非侵入性预测因子。
DOI：
10.1016/j.nicl.2018.10.014
发表时间：
2018
期刊：
NeuroImage. Clinical
影响因子：
--
作者：
Liu X;Li Y;Qian Z;Sun Z;Xu K;Wang K;Liu S;Fan X;Li S;Zhang Z;Jiang T;Wang Y
通讯作者：
Wang Y
DOI：
10.1056/nejmoa1707447
发表时间：
2017-12-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Neelapu SS;Locke FL;Bartlett NL;Lekakis LJ;Miklos DB;Jacobson CA;Braunschweig I;Oluwole OO;Siddiqi T;Lin Y;Timmerman JM;Stiff PJ;Friedberg JW;Flinn IW;Goy A;Hill BT;Smith MR;Deol A;Farooq U;McSweeney P;Munoz J;Avivi I;Castro JE;Westin JR;Chavez JC;Ghobadi A;Komanduri KV;Levy R;Jacobsen ED;Witzig TE;Reagan P;Bot A;Rossi J;Navale L;Jiang Y;Aycock J;Elias M;Chang D;Wiezorek J;Go WY
通讯作者：
Go WY
影响因子：
4.7
作者：
Liu J;Zhang S;Dai W;Xie C;Li JC
通讯作者：
Li JC
DOI：
10.1038/nrclinonc.2016.217
发表时间：
2017-07
期刊：
Nature reviews. Clinical oncology
影响因子：
--
作者：
Mantovani A;Marchesi F;Malesci A;Laghi L;Allavena P
通讯作者：
Allavena P
DOI：
10.1073/pnas.1409580111
发表时间：
2014-09-30
影响因子：
11.1
作者：
Laubli, Heinz;Pearce, Oliver M. T.;Varki, Ajit
通讯作者：
Varki, Ajit